View details of this raise on Seedstage

Houston, TX

Developing a biomedical AI to extend healthy lifespans globally.

• Global Collaborations: Biostate AI partners with leading hospitals worldwide to gather clinical data for its AI model.
• Cost-Effective Sequencing: The company has developed technologies to reduce the cost of DNA and RNA sequencing significantly.
• Experienced Leadership: Biostate AI’s team includes seasoned professionals in biotech and AI, supported by a world-class advisory board.
• Series A Funding: Accel led the Series A funding round, with early investors including notable figures in the biotech industry.
• Focus on Major Diseases: Research programs target diseases such as leukemia, lung cancer, and diabetes, among others.

Biostate AI is developing a general-purpose biomedical AI aimed at extending healthy lifespans by enabling 90% of people to live to 90 years old. The company collaborates with leading hospitals worldwide to gather clinical data, which is used to train its predictive medical AI, N-act. This model identifies early warning patterns that standard tests might miss, aiding doctors in making better-informed decisions. Biostate AI’s research focuses on diseases such as leukemia, lung cancer, melanoma, diabetes, lupus, multiple sclerosis, and heart disease.

Founded in 2023, Biostate AI has established a global presence with operations in the United States, China, India, and the Middle East. The company has developed cost-effective DNA and RNA sequencing technologies, significantly reducing the cost and increasing the scale of genetic analysis. Biostate AI’s leadership team, comprising experienced professionals in biotech and AI, is supported by an advisory board of world-class clinicians and researchers. The company’s Series A funding was led by Accel, with notable early investors including Dario Amodei and Emily Leproust. Biostate AI aims to create substantial value in the healthcare market by expanding its technology’s reach and impact.

Company Info

Biostate AI develops biomedical AI to extend healthy lifespan by analyzing large-scale molecular data for early disease detection.

Biostate AI is focused on developing a general-purpose biomedical AI aimed at extending healthy human lifespan. By leveraging big data and modern AI, the company seeks to help 90% of people live to 90 years old by understanding and addressing a wide range of diseases. Biostate collaborates with leading hospitals worldwide to gather real-world clinical data, which is used to train their predictive medical AI, N-act. This model is designed to identify early warning patterns in diseases such as leukemia, lung cancer, melanoma, diabetes, lupus, multiple sclerosis, and heart disease, enabling earlier and more informed medical decisions.

The company has developed innovative multiomics testing technologies that significantly reduce the cost of genetic analysis, making it more accessible. Biostate operates in the United States, China, India, and the Middle East, tapping into rapidly growing healthcare markets. Their leadership team combines expertise in biotech, AI, and international markets, positioning Biostate to scale its operations and translate scientific advancements into real-world healthcare improvements.